Clinic
Mercy Hospital of Buffalo
Mercy Hospital of Buffalo was paid $29.86M by Medicaid between Jan 2018 and Dec 2024, across 311 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoMERCY HOSPITAL OF BUFFALO
BUFFALO, NY 14220
BUFFALO, NY 14220
33aNPI1164464921assigned 06/13/2006
33bProvider typeCardiac Rehabilitation Clinic/Center
28Total paid$29.86M
24GClaims812,902
24DCodes billed311
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Cardiac Rehabilitation Clinic/Center providers in New York
Rank by total paid#1 of 5
Median peer was paid$13.42M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,833 | $922K | |
| 2019 | 75,415 | $2.72M | |
| 2020 | 127,404 | $4.73M | |
| 2021 | 143,819 | $5.58M | |
| 2022 | 143,121 | $5.56M | |
| 2023 | 165,528 | $5.96M | |
| 2024incomplete | 131,782 | $4.39M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 31,290 | 29,560 | $5.77M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 19,815 | 18,801 | $4.07M |
| G0378 | Hospital observation service, per hour | 12% | 3,677 | 2,375 | $3.49M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.5% | 10,370 | 10,038 | $1.65M |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.9% | 7,271 | 6,857 | $1.15M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.3% | 5,034 | 4,914 | $994K |
| 36415 | Collection of venous blood by venipuncture | 2.8% | 106,602 | 41,116 | $836K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.6% | 3,945 | 3,845 | $770K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.4% | 6,916 | 5,671 | $711K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.2% | 16,892 | 15,684 | $670K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 1.9% | 327 | 246 | $568K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.8% | 2,994 | 2,938 | $538K |
299 more codes
| 99214 | Doctor's office visit, returning patient (more involved) | 1.8% | 9,796 | $534K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 1.8% | 1,873 | $529K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.8% | 1,664 | $524K |
| 93976 | 1.5% | 1,710 | $444K | |
| 80053 | Comprehensive metabolic panel | 1.4% | 30,399 | $418K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.4% | 2,055 | $411K |
| 93458 | 1.0% | 250 | $313K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,730 | $289K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,452 | $274K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 7,795 | $219K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,869 | $201K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 7,520 | $197K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 25,038 | $184K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,635 | $178K |
| 47562 | <1% | 52 | $171K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 4,633 | $158K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,168 | $138K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,463 | $128K |
| C1821 | Interspinous process distraction device (implantable) | <1% | 25 | $123K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 3,183 | $112K |
| 76801 | <1% | 1,415 | $91K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,769 | $89K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,358 | $88K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,796 | $88K |
| 97161 | <1% | 1,531 | $86K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 19,934 | $80K |
| 87631 | <1% | 1,878 | $76K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,916 | $76K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,228 | $75K |
| 86850 | <1% | 4,537 | $74K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,868 | $69K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,147 | $68K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,372 | $64K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,950 | $64K |
| 93970 | <1% | 230 | $60K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 896 | $60K |
| 87481 | <1% | 1,831 | $59K | |
| 12001 | <1% | 209 | $59K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 872 | $55K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 17,252 | $55K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 814 | $54K |
| 93971 | <1% | 1,256 | $52K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,798 | $49K |
| 93975 | <1% | 146 | $48K | |
| 10060 | <1% | 225 | $45K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,120 | $45K |
| 99460 | <1% | 703 | $42K | |
| 86900 | <1% | 4,681 | $42K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,123 | $42K |
| 83880 | <1% | 2,120 | $40K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 256 | $36K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 506 | $35K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 764 | $34K |
| 97010 | <1% | 2,580 | $33K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,599 | $32K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,158 | $30K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,091 | $30K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 917 | $30K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 588 | $30K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,673 | $29K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 476 | $29K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 556 | $28K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,216 | $28K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,945 | $28K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 38,537 | $25K |
| 76830 | Ultrasound, transvaginal | <1% | 1,320 | $23K |
| 81025 | <1% | 9,175 | $23K | |
| 80061 | Lipid panel | <1% | 3,664 | $20K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 276 | $20K |
| 81513 | <1% | 1,992 | $20K | |
| 84702 | <1% | 6,676 | $18K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,570 | $18K |
| 88304 | <1% | 931 | $16K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 286 | $16K |
| 82607 | <1% | 1,729 | $16K | |
| 84439 | <1% | 2,097 | $16K | |
| 80076 | <1% | 1,976 | $15K | |
| 85027 | <1% | 5,829 | $14K | |
| 86901 | <1% | 1,183 | $13K | |
| 59426 | <1% | 109 | $13K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 204 | $13K |
| 59425 | <1% | 96 | $12K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 65 | $12K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 65 | $12K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 161 | $11K |
| 59025 | Fetal non-stress test | <1% | 520 | $11K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,533 | $11K |
| 90715 | <1% | 507 | $11K | |
| 72131 | <1% | 86 | $11K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,624 | $10K |
| 82746 | <1% | 1,178 | $10K | |
| 99000 | <1% | 755 | $10K | |
| 85610 | <1% | 10,988 | $10K | |
| C1781 | Mesh (implantable) | <1% | 24 | $10K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 123 | $10K |
| 72110 | <1% | 1,020 | $9K | |
| 12002 | <1% | 37 | $9K | |
| 90714 | <1% | 396 | $9K | |
| 85730 | <1% | 9,533 | $9K | |
| 86701 | <1% | 987 | $8K | |
| 81001 | <1% | 13,131 | $8K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 620 | $8K |
| 99462 | <1% | 280 | $8K | |
| 87563 | <1% | 477 | $8K | |
| 76813 | <1% | 212 | $8K | |
| 82803 | <1% | 618 | $7K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 944 | $7K |
| 97113 | <1% | 209 | $7K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 283 | $7K |
| 86803 | <1% | 1,134 | $7K | |
| 71045 | Radiologic examination, chest; single view | <1% | 7,985 | $6K |
| C1769 | Guide wire | <1% | 957 | $6K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 136 | $6K |
| 22853 | <1% | 28 | $6K | |
| G9007 | Coordinated care fee, scheduled team conference | <1% | 59 | $6K |
| 87660 | <1% | 3,170 | $6K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 104 | $6K |
| 29125 | <1% | 36 | $5K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 26 | $5K |
| 87340 | <1% | 673 | $4K | |
| 81003 | <1% | 6,191 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,209 | $4K |
| 94727 | <1% | 267 | $4K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 98 | $4K |
| 83735 | <1% | 7,055 | $4K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 13 | $4K |
| 97162 | <1% | 69 | $4K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,754 | $4K |
| 72100 | <1% | 439 | $4K | |
| 73630 | <1% | 1,607 | $3K | |
| 99201 | <1% | 34 | $3K | |
| 70486 | <1% | 76 | $3K | |
| 86780 | <1% | 328 | $3K | |
| 99406 | <1% | 340 | $3K | |
| 85652 | <1% | 2,009 | $3K | |
| 94729 | <1% | 160 | $3K | |
| 82948 | <1% | 4,593 | $3K | |
| 86762 | <1% | 236 | $2K | |
| 82728 | <1% | 213 | $2K | |
| 99385 | <1% | 27 | $2K | |
| 73030 | <1% | 1,118 | $2K | |
| 99441 | <1% | 78 | $2K | |
| 72040 | <1% | 373 | $2K | |
| 93041 | <1% | 185 | $2K | |
| 88312 | <1% | 215 | $2K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 38 | $2K |
| 73610 | <1% | 1,430 | $2K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 211 | $2K |
| 84484 | <1% | 13,082 | $2K | |
| 76818 | <1% | 51 | $2K | |
| 73564 | <1% | 621 | $2K | |
| 99223 | Prolong inpt eval add15 m | <1% | 12 | $2K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 21 | $2K |
| 83655 | <1% | 110 | $2K | |
| 73130 | <1% | 1,250 | $1K | |
| 93017 | <1% | 43 | $1K | |
| 87077 | <1% | 2,193 | $1K | |
| 73562 | <1% | 422 | $1K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 12 | $1K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 57 | $1K |
| J3490 | Unclassified drugs | <1% | 2,454 | $1K |
| 90686 | <1% | 60 | $1K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 302 | $1K |
| 83550 | <1% | 326 | $1K | |
| 88311 | <1% | 50 | $1K | |
| 76536 | <1% | 26 | $1K | |
| 74018 | <1% | 355 | $1K | |
| 83690 | <1% | 10,624 | $1K | |
| 81002 | <1% | 1,840 | $1K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 12 | $1K |
| 87186 | <1% | 1,941 | $1K | |
| 82043 | <1% | 233 | $1K | |
| 85379 | <1% | 2,592 | $1K | |
| 86140 | <1% | 402 | $1K | |
| 90688 | <1% | 60 | $1K | |
| 82150 | <1% | 6,650 | $1K | |
| 94060 | <1% | 32 | $989.22 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,829 | $962.31 |
| 87070 | <1% | 1,708 | $924.16 | |
| 99383 | <1% | 12 | $842.66 | |
| 99442 | <1% | 15 | $837.69 | |
| 90670 | <1% | 112 | $759.97 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,600 | $754.89 |
| 87040 | <1% | 3,132 | $712.54 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 12 | $671.56 |
| 76775 | <1% | 13 | $651.57 | |
| 84153 | <1% | 38 | $630.83 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 132 | $627.97 |
| 82550 | <1% | 1,472 | $621.81 | |
| 72050 | <1% | 54 | $610.28 | |
| 87081 | <1% | 1,491 | $600.22 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,687 | $573.45 |
| 97597 | <1% | 19 | $529.84 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,512 | $522.98 |
| 90648 | <1% | 100 | $519.81 | |
| 73502 | <1% | 144 | $439.43 | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,197 | $389.97 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,755 | $385.16 |
| 73110 | <1% | 436 | $378.53 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,927 | $374.11 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 391 | $368.72 |
| 83605 | <1% | 2,130 | $359.49 | |
| 99152 | <1% | 847 | $354.11 | |
| 73100 | <1% | 207 | $336.99 | |
| 90658 | <1% | 268 | $292.40 | |
| 73590 | <1% | 209 | $286.85 | |
| 83021 | <1% | 13 | $284.41 | |
| 85007 | <1% | 1,267 | $254.97 | |
| 90710 | <1% | 26 | $246.39 | |
| 76641 | <1% | 12 | $233.44 | |
| 90696 | <1% | 29 | $232.05 | |
| 90633 | <1% | 24 | $215.82 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,807 | $209.17 |
| 83540 | <1% | 53 | $199.37 | |
| 90723 | <1% | 27 | $198.51 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,800 | $193.28 |
| 86787 | <1% | 22 | $183.10 | |
| 87205 | <1% | 779 | $174.04 | |
| 84146 | <1% | 12 | $169.33 | |
| 81015 | <1% | 982 | $157.74 | |
| 83001 | <1% | 12 | $148.24 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,875 | $144.37 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,633 | $138.52 |
| 82947 | <1% | 57 | $134.15 | |
| A9270 | Non-covered item or service | <1% | 14,523 | $123.27 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,714 | $122.34 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 54 | $121.30 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 721 | $121.15 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,231 | $119.17 |
| 82570 | <1% | 45 | $118.43 | |
| 84156 | <1% | 56 | $79.21 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 41 | $78.96 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 327 | $76.72 |
| 82247 | <1% | 44 | $75.90 | |
| 73090 | <1% | 57 | $69.07 | |
| 86308 | <1% | 403 | $61.98 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,576 | $56.68 |
| 73080 | <1% | 123 | $55.95 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 584 | $52.72 |
| 87480 | <1% | 96 | $51.51 | |
| 87510 | <1% | 96 | $46.68 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,064 | $43.01 |
| 71101 | <1% | 66 | $42.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 519 | $41.82 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 915 | $36.25 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 691 | $34.88 |
| 84550 | <1% | 14 | $31.64 | |
| 99173 | <1% | 73 | $30.82 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,995 | $30.33 |
| 80348 | <1% | 65 | $30.10 | |
| 94760 | <1% | 249 | $29.73 | |
| 80320 | <1% | 725 | $26.58 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 283 | $24.80 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,165 | $23.79 |
| 84460 | <1% | 26 | $20.32 | |
| 87075 | <1% | 47 | $18.94 | |
| 86403 | <1% | 54 | $17.83 | |
| 73140 | <1% | 12 | $17.29 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 726 | $15.90 |
| 80179 | <1% | 179 | $15.58 | |
| 82565 | <1% | 14 | $15.34 | |
| 84155 | <1% | 27 | $14.68 | |
| J2305 | Injection, nitroglycerin, 5 mg | <1% | 42 | $13.64 |
| 74019 | <1% | 14 | $13.45 | |
| 87590 | <1% | 201 | $12.99 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 910 | $11.95 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 220 | $11.49 |
| 87285 | <1% | 25 | $10.95 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 77 | $7.20 |
| 82040 | <1% | 15 | $6.74 | |
| 96376 | <1% | 2,037 | $6.60 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 367 | $6.24 |
| 73060 | <1% | 12 | $6.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 57 | $3.87 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 865 | $2.92 |
| J1643 | Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units | <1% | 275 | $2.80 |
| 87147 | <1% | 58 | $2.58 | |
| J0132 | Injection, acetylcysteine, 100 mg | <1% | 229 | $1.04 |
| 80329 | <1% | 149 | $0.83 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 26 | $0.36 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 144 | $0.12 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 81 | $0.00 |
| 99080 | 0% | 1,452 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 80 | $0.00 |
| 82010 | 0% | 144 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 150 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 14 | $0.00 |
| 90734 | 0% | 32 | $0.00 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 16 | $0.00 |
| 71100 | 0% | 13 | $0.00 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 0% | 37 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 43 | $0.00 |
| 84075 | 0% | 12 | $0.00 | |
| 74022 | 0% | 145 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 94 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 30 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 39 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 23 | $0.00 |
| 90651 | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMACHOLZ, DAVID (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Mount ST. Mary's Hospital of Niagara Falls | Lewiston, NY | $22.19M |
| Sisters of Charity Hospital of Buffalo New York | Cheektowaga, NY | $13.42M |
| Sisters of Charity Hospital of Buffalo New York | Buffalo, NY | $3.93M |
| Mount ST. Mary's Hospital of Niagara Falls | Lewiston, NY | $2.87M |
| Mercy Hospital of Buffalo | Buffalo, NY | $449K |
| Kenmore Mercy Hospital | Kenmore, NY | $70K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.